跳转至内容
Merck

890850C

Avanti

18:1 DAP

Avanti Research - A Croda Brand 890850C

别名:

1,2-二油酰-3-二甲基铵-丙烷(DODAP)

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C41H77NO4
分子量:
648.05
分類程式碼代碼:
12352211
NACRES:
NA.25

形狀

liquid

包裝

pkg of 1 × 2.5 mL (890850C-25mg)
pkg of 2 × 4 mL (890850C-200mg)

製造商/商標名

Avanti Research - A Croda Brand 890850C

濃度

10 mg/mL (890850C-25mg)
25 mg/mL (890850C-200mg)

脂質類型

transfection
cationic lipids

運輸包裝

dry ice

儲存溫度

−20°C

SMILES 字串

[H]C(CN(C)C)(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCC/C=C\CCCCCCCC)=O

InChI

1S/C41H77NO4/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-40(43)45-38-39(37-42(3)4)46-41(44)36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h19-22,39H,5-18,23-38H2,1-4H3/b21-19-,22-20-

InChI 密鑰

NYDLOCKCVISJKK-WRBBJXAJSA-N

一般說明

18:1 DAP是一种阳离子脂质。作为pH敏感性转染试剂,可用于制备阳离子脂质体。

應用

18:1 DAP适用于:
  • 作为脂质双分子层组分
  • 制备稳定的核酸脂质囊泡
  • 含反义寡脱氧核糖核苷酸(ODN)的叶酸(FA)靶向脂质体和非靶向脂质体的制备和理化特性表征

包裝

5 mL透明玻璃密封安瓿(890850C-200mg)
5 mL透明玻璃密封安瓿(890850C-25mg)

法律資訊

Avanti Research is a trademark of Avanti Polar Lipids, LLC

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險分類

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 Oral - STOT SE 3

標靶器官

Liver,Kidney, Respiratory system

儲存類別代碼

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

does not flash

閃點(°C)

does not flash


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Transferrin-conjugated SNALPs encapsulating 2?-O-methylated miR-34a for the treatment of multiple myeloma
Scognamiglio I, et al.
BioMed Research International, 2014 (2014)
Preparation and in-vitro evaluation of an antisense-containing cationic liposome against non-small cell lung cancer: a comparative preparation study
Saffari M, et al.
Iranian Journal of Pharmaceutical Research : IJPR, 12, 3-3 (2013)
Nonequilibrium adhesion patterns at lipid bilayer junctions
Parthasarathy R, et al.
The Journal of Physical Chemistry B, 108(2), 649-657 (2004)
Qiang Cheng et al.
Nature nanotechnology, 15(4), 313-320 (2020-04-07)
CRISPR-Cas gene editing and messenger RNA-based protein replacement therapy hold tremendous potential to effectively treat disease-causing mutations with diverse cellular origin. However, it is currently impossible to rationally design nanoparticles that selectively target specific tissues. Here, we report a strategy

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门